KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-Current Deffered Revenue: 2009-2011

Historic Non-Current Deffered Revenue for Acadia Pharmaceuticals (ACAD) over the last 3 years, with Dec 2011 value amounting to $2.6 million.

  • Acadia Pharmaceuticals' Non-Current Deffered Revenue fell 3.02% to $2.4 million in Q2 2012 from the same period last year, while for Jun 2012 it was $2.4 million, marking a year-over-year decrease of 3.02%. This contributed to the annual value of $2.6 million for FY2011, which is 1.37% down from last year.
  • According to the latest figures from FY2011, Acadia Pharmaceuticals' Non-Current Deffered Revenue is $2.6 million, which was down 1.37% from $2.6 million recorded in FY2010.
  • In the past 5 years, Acadia Pharmaceuticals' Non-Current Deffered Revenue registered a high of $22.6 million during FY2009, and its lowest value of $2.6 million during FY2011.
  • In the last 3 years, Acadia Pharmaceuticals' Non-Current Deffered Revenue had a median value of $2.6 million in 2010 and averaged $9.3 million.
  • Data for Acadia Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY plummeted of 88.38% (in 2010) over the last 5 years.
  • Over the past 3 years, Acadia Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $22.6 million in 2009, then plummeted by 88.38% to $2.6 million in 2010, then declined by 1.37% to $2.6 million in 2011.